Evidence map›Paper›PMID 40635858›Full record

ReviewiLIVER2024

Arginine methylation modification in the malignant progression of benign and malignant liver diseases.

Jie-Zuo Huang, Bei-Ning Qiao, Dang-Chi Li, Qiu-Rong Wei, Zi-Jian Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in iLIVER, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jie-Zuo HuangCollege of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.
Bei-Ning QiaoCollege of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.
Dang-Chi LiDepartment of Ecology and Evolutionary Biology, University of California, Los Angeles, 612, Charles E. Young Drive East, Los Angeles 90095, CA, USA.
Qiu-Rong WeiDepartment of Pediatrics, Chibi People's Hospital, Xianning 437300, China.
Zi-Jian ZhangDepartment of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of protein arginine methyltransferases (PRMTs) in benign and malignant liver diseases has garnered considerable attention. PRMTs play a key function in regulating protein methylation modification in diseases such as alcoholic fatty liver disease, metabolic dysfunction-associated steatotic liver disease, viral hepatitis, and hepatocellular carcinoma. This review explores the mechanisms of action of PRMTs in these diseases, with a focus on their effects on cell signaling, transcriptional regulation, cell proliferation, and metabolism. We also discuss potential therapeutic strategies targeting PRMTs and propose future research directions. This review helps deepen the understanding of the important role of arginine methylation modification in the malignant progression of liver diseases and provides guidance for future clinical treatment and drug development.

Indexed as

Alcoholic liver diseaseArginine methyltransferasesHepatocellular carcinomaLiver diseasesMetabolic dysfunction–associated steatotic liver diseaseMetabolismNon-alcoholic liver diseaseTherapeutic strategiesViral hepatitis

Identifiers

PMID40635858
PMCPMC12212703

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.